Abstract
Cardiovascular disease (CVD) is the leading cause of mortality in Western populations. It is also known that the lifelong risk for CVD is higher for men than women; however, in postmenopausal women, risk for CVD elevates more rapidly than among same-aged men. Although epidemiological studies indicate that CVD risk is reduced in postmenopausal hormone replacement therapy (HRT) users, this was not confirmed by the initial results of the randomized Women’s Health Initiative (WHI) trial. Interestingly, after several reanalyses also WHI data indicate that HRT after all provide CVD protection if initiated close to menopause, as was the case in observational studies. Furthermore, new clinical data show that cardiovascular mortality risk is reduced among HRT users.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133(12):933–41.
Mikkola TS, Savolainen-Peltonen H, Venetkoski M, Ylikorkala O. New evidence for cardiac benefit of postmenopausal hormone therapy. Climacteric. 2017;20:5–10.
Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: cronary heart disease events associated with hormone therapy in younger and older women - a meta-analysis. J Gen Intern Med. 2006;21(4):363–6.
Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause. 2015;22(9):976–83.
Savolainen-Peltonen H, Tuomikoski P, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Cardiac death risk in relation to the age at initiation or the progestin component of hormone therapies. J Clin Endocrinol Metab. 2016;101:2794–801.
Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–77.
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality – the Women’s Health Initiative randomized trials. JAMA. 2017;318:927–38.
Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299:1036–45.
Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49–57.
Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab. 2015;100:4588–94.
Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Increased cardiac death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause. 2018;25:375–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 International Society of Gynecological Endocrinology
About this chapter
Cite this chapter
Mikkola, T.S. (2019). Cardiovascular Mortality Risk and HRT. In: Brinton, R., Genazzani, A., Simoncini, T., Stevenson, J. (eds) Sex Steroids' Effects on Brain, Heart and Vessels. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-030-11355-1_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-11355-1_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-11354-4
Online ISBN: 978-3-030-11355-1
eBook Packages: MedicineMedicine (R0)